A ngiotensin-converting enzyme (ACE) inhibitors are widely used after myocardial infarction, with improvement in survival and reduced morbidity and mortality.12 The purported mechanisms by which ACE inhibitors exert their effects are the attenuation of ventricular remodeling and the inhibition of neurohumoral activation. However, other mechanisms may account for the beneficial effects recently reported on ventricular arrhythmias and sudden death. 3 Signs of sympathovagal imbalance have been consistently found after myocardial infarction,4-6 and changes in autonomic tone may potentially contribute to adverse pathophysiological events such as malignant ventricular arrhythmias. Heart period variability has been shown to be a reliable noninvasive method for quantitative assessment of cardiac autonomic control.7-9 Moreover, power in the lower-frequency bands and in particular, ultralow-frequency (ULF) and very-low-frequency power (VLF) are strongly associated with all-cause mortality, cardiac death, and arrhythmic death after myocardial infarction.10 It has been reported that fluctuations in activity of the renin-angiotensin system modulate ULF and VLF power"; thus, it will be interesting and important to know whether the blockade of the reninangiotensin system after myocardial infarction would improve ULF and VLF components of the power spectrum and their correlates in the time domain.
The purpose of the present investigation was to analyze in a double-blind placebo-controlled study the effects of captopril administration on time-and frequency-domain measures of heart period variability in patients with a first acute myocardial infarction. A favorable effect of captopril on heart period variability may reflect an improvement in cardiac autonomic control that could be an additive mechanism by which ACE inhibitors improve outcome after myocardial infarction.
Methods Study Patients
The study group consisted of 40 patients referred to our coronary care unit for a first Q-wave myocardial infarction diagnosed by classic criteria; the site of necrosis was anterior in 23 and inferior in 17.
Exclusion criteria were age >69 years, non-Q-wave necro- There is a body of knowledge about the behavior and significance of the different time-domain measures used for heart period variability assessment. In this study, from the time series of normal RR (NN) intervals we calculated the six time-domain variables defined in Table 1 . The SD of all normal RR (NN) intervals (SDNN) depends on the basic day/night difference in mean RR and to a lesser extent on short-term variations in heart rate and may be considered a broad-band measure of autonomic balance. Also, the SD of the average NN intervals for all 5-minute segments (SDANN index) evaluates long-term RR variations, whereas the mean of the SDs of all NN intervals for all 5-minute segments (SDNN index) depends on short-term RR variations. Differences between successive NN intervals provide an index of vagal activity that is firmly related to short-term variations in heart rate. Accordingly, we computed the absolute value of each individual difference between adjacent NN intervals and summarized the differences by the percentage of differences exceeding 50 milliseconds for the entire 24 hours (pNN50). In addition, the root mean square successive difference (r-MSSD), a continuous measure of vagal tone, was calculated on the 24-hour NN intervals with the formula of von Neumann et al. 13 Because this parameter takes account of the time order of the NN intervals, it is not much influenced by gradual trends and, theoretically, is a better measure of short-term variability than SDNN.
Frequency-Domain Measures of Heart Period Variability
Frequency-domain measures of heart period variability compose a mutually exclusive, all-inclusive categorization of heart period variability. In this study, we computed the heart period power spectrum by means of the fast Fourier transform algorithm, averaging 42 spectra of 25 minutes for a total of 17 
Results

Baseline Characteristics
Characteristics of the study population and control group are reported in Table 2 . No difference was detectable between placebo and captopril groups with regard to clinical characteristics, peak creatine kinase values, plasma renin activity, and baseline time-and frequency-domain measures of heart period variability.
Time-Domain Measures
The effects of captopril administration on the normal RR (NN) intervals and on the time domain of heart period variability are reported in Table 3 . After captopril, SDNN increased by 17%, SDANN index by 22%, and SDNN index by 9%, while the 24-hour average NN interval, r-MSSD, and pNN50 remained unchanged. After placebo, all time-domain measures of heart period variability remained unchanged (Table 4) .
Frequency-Domain Measures
Captopril induced significant changes in the heart period power spectrum ( (P<.01). In the control group, no difference was detectable for plasma renin activity after placebo administration.
Discussion
This study first evaluated, in myocardial infarction patients, the effects of an ACE inhibitor, captopril, on time-and frequency-domain measures of heart period variability. The results clearly demonstrate that the inhibition of the renin-angiotensin system after captopril administration improves the heart period variability components more strictly related to mortality after myocardial infarction. Furthermore, our data confirm that the renin-angiotensin system modulates the lowerfrequency components of the power spectrum in the setting of acute myocardial infarction as well. Heart Period Variability and Acute
Myocardial Infarction
Signs of sympathovagal imbalance have been consistently reported after myocardial infarction,4-6 and heart period variability is increasingly being used as a marker of this autonomic disturbance.
At baseline in our study population, time-and frequency-domain measures of heart period variability were far below those reported in normal subjects.18,20 Frequencydomain measures were also lower than those found by Bigger et a118 in myocardial infarction patients. However, our patients underwent their first 24-hour Holter recording 3 to 4 days after infarction, whereas in the study by Bigger et al, baseline evaluation was at a mean of 25 days after the acute event. Furthermore, it must be considered that in our study, we computed the average power of the total spectrum between 0.00066 and 0.40 Hz (spectra computed from 25-minute segnents of the ECG); the lack of power <0.00066 Hz explains the lower values we observed in total power and in its ULF component.
Measures of Heart Period Variability as Risk Predictors After Myocardial Infarction
Kleiger et a12P first found that the SD of normal RR intervals computed over 24 hours predicts all-cause mortality after myocardial infarction independently of the major risk factors. Subsequent studies, all relatively small, demonstrated that other measures of heart period variability such as HF power or SDNN index might predict sudden cardiac death better than SDNN. 22, 23 Recently, Bigger et al,'0 using power spectrum analysis, reported that, after adjustment for other previously established risk predictors, a strong association was detectable between mortality and total, ULF, and VLF power, whereas LF and HF power were only moderately associated. These researchers pointed out that it will be interesting and important to determine the source of ULF and VLF power because these components of the heart period power spectrum are such powerful independent predictors of mortality and concluded that a better understanding of the origin of changes in these components could lead to hypotheses about interventions aimed at improving After captopril, SDNN, SDANN index, and SDNN index increased significantly and in agreement with the correlation existing between time-and frequency-domain measures of heart period variability.12 LF, ULF, VLF, and total power were higher after captopril. Conversely, captopril had no effect on pNN50, r-MSSD, and HF power, considered to be pure indexes of the modulation of vagal tone by respiratory frequency and depth.8'9'28 '29 The changes observed in our patients after captopril seem to be physiologically meaningful. In fact, even if the increase in heart period variability is only an indirect measure of benefit, the change in SDNN from 90+29 to 105+±30 milliseconds is relevant. It must be taken into consideration that in the study by Kleiger et al, 21 patients with SDNN> 100 milliseconds had a better prognosis, and in a recent investigation performed in myocardial infarction patients, SDNN was 81±40 in those with inducible ventricular tachycardia and 122+43 in those without. 27 Mechanism of the Improvement in Heart Period Variability After Captopril
In our opinion, the blockade of the renin-angiotensin system plays a central role in determining the modificatopril. ACE inhibition certainly occurred in our patients, because, although we did not measure angiotensin II levels, plasma renin activity doubled after captopril but not after placebo.
Lumbers et a130 reported that angiotensin II inhibits vagal parasympathetic outflow through a central nervous mechanism. Thus, the blockade of the reninangiotensin system might be expected to increase vagal activity, which should increase HF power. Contrary to this expectation, Akselrod et all' found no change in HF peak after ACE inhibition and an increase in the peak of frequency located at 0.04 Hz; this author hypothesized that the tonic activity of the renin-angiotensin system normally damps the amplitude of this latter spectral component.
Our study confirms that the effect of ACE inhibition on heart period variability is selective, does not interfere with HF power, and offers new insight into the source of ULF and VLF power. In fact, the reduction in ULF and VLF power is probably due to the activation of the renin-angiotensin system that occurs early after acute myocardial infarction31; the increase in these two components after captopril is in agreement with this hypothesis.
LF power is a measure of the modulation of both sympathetic9 and parasympathetic systems32 by baroreflex activity. The increase in LF power induced by captopril may reflect an increase in heart rate fluctuations in this frequency band caused by an increased gain of baroreceptor response to oscillatory blood pressure variations; the favorable effect of captopril on baroreflex sensitivity33 supports this hypothesis. However, an increase in LF blood pressure fluctuations after captopril, which then elicit increased heart rate fluctuations, cannot be excluded. 89 We must consider that during Holter recordings, unlike other controlled conditions,34 activity and posture are uncontrolled, making interpretation of the LF band of the heart period power spectrum more difficult. 35 
Clinical Implications
The results of the SAVE trial1 demonstrated that captopril administration after myocardial infarction improves the outcome of patients with left ventricular dysfunction. Moreover, in a subgroup of patients with available Holter recordings, captopril demonstrated favorable and parallel effects on ventricular arrhythmias and sudden death.3 It must be taken into consideration that after myocardial infarction, captopril improves left ventricular remodeling and function36 and, therefore, the changes we observed in heart period variability may be secondary to the hemodynamic improvement. However, no patients in our study showed clinical signs of heart failure, and the correlation between heart period variability and left ventricular ejection fraction is remarkably weak,12 particularly in patients with subsequent arrhythmic events.37 Therefore, we hypothesize that even part of the beneficial effects of ACE inhibitors is due to a direct effect on cardiac autonomic control.
Study Limitations
Our results seem attractive, but because of the small number of patients and the exclusion criteria adopted, doubt must exist as to the applicability of these findings tion of heart period variability we observed after capto myocardial infarction patients as a whole. SpeciAc target studies are necessary to clarify how much of the beneficial effects of ACE inhibitors depends on the change in cardiac autonomic control.
Conclusions
In our myocardial infarction patients, captopril administration favorably modified time-and frequencydomain measures of heart period variability strongly associated with all-cause mortality, cardiac death, and arrhythmic death during follow-up. Thus, the recovery in ULF, VLF, and LF power may help to explain the beneficial effect of ACE inhibition independent of the attenuation of left ventricular remodeling.
